Haleon and the University of Sydney drive new osteoarthritis research

Haleon and the University of Sydney drive new osteoarthritis research

• Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for osteoarthritis
• The collaboration will develop innovative, evidence-based strategies to help improve osteoarthritis management in Australia, and globally
• Osteoarthritis is a painful and debilitating condition that affects over 2 million Australians, representing a significant public health burden, a leading cause of disability and reduced quality of life¹

Haleon, a leading consumer healthcare company, is sponsoring a five-year fellowship at the University of Sydney focused on exploring the therapeutic benefits of supplements for managing osteoarthritis symptoms and the use of digital health technologies to enhance mobility.

Osteoarthritis, a major cause of disability, affects over 2 million Australians and 595 million people worldwide, posing a significant public health challenge and reducing quality of life for aging populations.

The fellowship will support a postdoctoral researcher under the mentorship of renowned osteoarthritis expert, rheumatologist, and researcher, Professor David Hunter.

Photo by Boost Physiotherapy

Professor Hunter said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”

“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.

Haleon, the company behind popular health products like Panadol, Voltaren, Centrum, and Caltrate, is partnering with the University of Sydney to pursue better management strategies for osteoarthritis and improve outcomes for those affected.

Dr. Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, emphasised that the fellowship aligns with Haleon’s dedication to advancing science and innovation in consumer healthcare.

“As global leaders in pain management and everyday health, Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes. This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Thampi.